In a Phase 3 trial, the daily pill orforglipron outperformed oral semaglutide for weight loss (15-20 lbs) and cardiovascular markers. As a small molecule, it requires no refrigeration and is cheaper to scale, though 10% of users quit due to gastrointestinal side effects. - 新闻列表